These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 26530749)

  • 21. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
    Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study.
    Ch'ang HJ; Lin YL; Wang HP; Chiu YF; Chang MC; Hsu CH; Tien YW; Chen JS; Hsieh RK; Lin PW; Shan YS; Cheng AL; Chang JY; Whang-Peng J; Hwang TL; Chen LT
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e749-57. PubMed ID: 21420250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quality of life in a prospective, multicenter phase 2 trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma.
    Serrano PE; Herman JM; Griffith KA; Zalupski MM; Kim EJ; Bekaii-Saab TS; Ben-Josef E; Dawson LA; Ringash J; Wei AC
    Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):270-7. PubMed ID: 25104069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group trial, JCOG1106.
    Ioka T; Furuse J; Fukutomi A; Mizusawa J; Nakamura S; Hiraoka N; Ito Y; Katayama H; Ueno M; Ikeda M; Sugimori K; Okano N; Shimizu K; Yanagimoto H; Okusaka T; Ozaka M; Todaka A; Nakamori S; Tobimatsu K; Sata N; Kawashima Y; Hosokawa A; Yamaguchi T; Miyakawa H; Hara H; Mizuno N; Ishii H;
    Jpn J Clin Oncol; 2021 Feb; 51(2):235-243. PubMed ID: 33164066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.
    Bernhard J; Dietrich D; Scheithauer W; Gerber D; Bodoky G; Ruhstaller T; Glimelius B; Bajetta E; Schüller J; Saletti P; Bauer J; Figer A; Pestalozzi BC; Köhne CH; Mingrone W; Stemmer SM; Tàmas K; Kornek GV; Koeberle D; Herrmann R;
    J Clin Oncol; 2008 Aug; 26(22):3695-701. PubMed ID: 18669454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer.
    Shaikh T; Wang LS; Egleston B; Burki M; Hoffman JP; Cohen SJ; Meyer JE
    Am J Clin Oncol; 2018 Jan; 41(1):59-64. PubMed ID: 26325492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.
    Cunningham D; Chau I; Stocken DD; Valle JW; Smith D; Steward W; Harper PG; Dunn J; Tudur-Smith C; West J; Falk S; Crellin A; Adab F; Thompson J; Leonard P; Ostrowski J; Eatock M; Scheithauer W; Herrmann R; Neoptolemos JP
    J Clin Oncol; 2009 Nov; 27(33):5513-8. PubMed ID: 19858379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation.
    Koay EJ; Zaid M; Aliru M; Bagereka P; Van Wieren A; Rodriguez MJ; Jacobson G; Wolff RA; Overman M; Varadhachary G; Pant S; Wang H; Tzeng CW; Ikoma N; Kim M; Lee JE; Katz MH; Tamm E; Bhosale P; Taniguchi CM; Holliday EB; Smith GL; Ludmir EB; Minsky BD; Crane CH; Koong AC; Das P; Wang X; Javle M; Krishnan S
    Int J Radiat Oncol Biol Phys; 2022 Nov; 114(3):444-453. PubMed ID: 35863672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer.
    Rao AD; Sugar EA; Chang DT; Goodman KA; Hacker-Prietz A; Rosati LM; Columbo L; O'Reilly E; Fisher GA; Zheng L; Pai JS; Griffith ME; Laheru DA; Iacobuzio-Donahue CA; Wolfgang CL; Koong A; Herman JM
    Pract Radiat Oncol; 2016; 6(6):417-424. PubMed ID: 27552809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concurrent chemoradiotherapy with or without induction chemotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer.
    Huang WK; Kuo YC; Tsang NM; Hsu HC; Shen WC; Chou WC; Yang TS; Chen JS
    Anticancer Res; 2014 Nov; 34(11):6755-61. PubMed ID: 25368287
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemoradiotherapy after gemcitabine plus erlotinib in patients with locally advanced pancreatic cancer.
    Kim E; Kim K; Kyu Chie E; Oh DY; Tae Kim Y
    J BUON; 2017; 22(4):1046-1052. PubMed ID: 28952226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea.
    Lee HS; Chung MJ; Park JY; Bang S; Park SW; Kim HG; Noh MH; Lee SH; Kim YT; Kim HJ; Kim CD; Lee DK; Cho KB; Cho CM; Moon JH; Kim DU; Kang DH; Cheon YK; Choi HS; Kim TH; Kim JK; Moon J; Shin HJ; Song SY;
    Medicine (Baltimore); 2017 Jan; 96(1):e5702. PubMed ID: 28072706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative Study Between Gemcitabine-Based and Gemcitabine Plus S1-Based Preoperative Chemoradiotherapy for Localized Pancreatic Ductal Adenocarcinoma, With Special Attention to Initially Locally Advanced Unresectable Tumor.
    Takeuchi T; Mizuno S; Murata Y; Hayasaki A; Kishiwada M; Fujii T; Iizawa Y; Kato H; Tanemura A; Kuriyama N; Azumi Y; Usui M; Sakurai H; Isaji S
    Pancreas; 2019 Feb; 48(2):281-291. PubMed ID: 30629019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction chemotherapy followed by chemoradiation in locally advanced pancreatic cancer: an effective and well-tolerated treatment.
    Hudson E; Hurt C; Mort D; Brewster AE; Iqbal N; Joseph G; Crosby TD; Mukherjee S
    Clin Oncol (R Coll Radiol); 2010 Feb; 22(1):27-35. PubMed ID: 19896352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Locally advanced unresectable pancreatic cancer.
    Johung KL; Saif MW; Chang BW
    JOP; 2014 Jul; 15(4):329-31. PubMed ID: 25076335
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality of life of locally advanced cervical cancer patients after neoadjuvant chemotherapy followed by chemoradiation versus chemoradiation alone (CIRCE trial): a randomized phase II trial.
    Nunes de Arruda F; da Costa S; Bonadio R; Dornellas A; Pereira D; de Bock GH; Del Pilar Estevez Diz M
    Int J Gynecol Cancer; 2020 Jun; 30(6):749-756. PubMed ID: 32321767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.
    Herrmann R; Bodoky G; Ruhstaller T; Glimelius B; Bajetta E; Schüller J; Saletti P; Bauer J; Figer A; Pestalozzi B; Köhne CH; Mingrone W; Stemmer SM; Tàmas K; Kornek GV; Koeberle D; Cina S; Bernhard J; Dietrich D; Scheithauer W; ;
    J Clin Oncol; 2007 Jun; 25(16):2212-7. PubMed ID: 17538165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.
    Ke QH; Zhou SQ; Yang JY; Du W; Liang G; Lei Y; Luo F
    World J Gastroenterol; 2014 Oct; 20(38):13987-92. PubMed ID: 25320537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-Term Health-Related Quality of Life in Patients With Rectal Cancer After Preoperative Short-Course and Long-Course (Chemo) Radiotherapy.
    Wiltink LM; Nout RA; van der Voort van Zyp JR; Ceha HM; Fiocco M; Meershoek-Klein Kranenbarg E; Marinelli AW; van de Velde CJ; Marijnen CA
    Clin Colorectal Cancer; 2016 Sep; 15(3):e93-9. PubMed ID: 26968237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.